University of Oxford-founded OMass Therapeutics has extended its series A round to progress a pipeline targeting immunological and genetic disorders.
Sonoma Biotherapeutics has emerged from stealth with $40m to develop regulatory T-cell therapies for autoimmune and degenerative diseases.
Verily has taken part in an oversubscribed series B round that will fund the UC Berkeley spinout's expansion from diagnostics to gene editing and drug development.
Stanford-StartX's Zinier took its overall funding to $120m in a round that included returning investor Qualcomm Ventures, with the cash to go to international growth and product development.
Jasper Therapeutics, based in part on Stanford research, has raised a $15m series A extension on the back of early clinical results from its blood transplant conditioning program.
Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.